Susquehanna International Group’s ProShares Ultra CRCL CRCA Stock Holding History

Susquehanna International Group’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$887K	Buy	21,484 +7,384	+52%	+$307K	﹤0.01%	8204
2025 Q4	$570K	Buy	+14,100	New	+$1.21M	﹤0.01%	8473

Other funds holding CRCA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Susquehanna International Group's CRCA Position: Q1 2026 in Review

Susquehanna International Group increased its ProShares Ultra CRCL (CRCA) stake by 52% in Q1 2026, buying an estimated $307K and bringing the position to 21,484 shares worth $887K. The position accounts for ﹤0.01% of the portfolio, ranked #8204.

Susquehanna International Group first reported a position in CRCA in Q4 2025 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold CRCA as of Q1 2026.

Susquehanna International Group held 21,484 shares of ProShares Ultra CRCL worth $887K as of Q1 2026.
Susquehanna International Group bought 7,384 ProShares Ultra CRCL shares in Q1 2026, an estimated $307K.
ProShares Ultra CRCL made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8204 holding.
Susquehanna International Group first reported a position in ProShares Ultra CRCL in Q4 2025 and has held it in 2 quarters since.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.